Cancer | Promoter | Vector | Construct | Transgene/Feature | Administration | Phase | ClinicalTrials. gov ID | Ref. | Combination |
---|---|---|---|---|---|---|---|---|---|
Bladder cancer | E2F1 | CG0070 | Ad5-E2F-E1A-GM-CSF | GM-CSF | Intravesical | Phase III | NCT04452591 | [111] | N-dodecyl-B-D-maltoside |
Melanoma | ICOVIR-5 | Ad5-E2F-∆24-RGD4C | Intravenous | Phase I | NCT01864759 | [119] | |||
Solid tumor | ICOVIR-7 | Ad5-E2F-palin-∆24-RGD4C | E2F palindromes | Intravenous | Preclinical | [120] | |||
Solid tumor | ICOVIR-15K-cBiTE | Ad5-E2F-∆24-RGD4C-cBiTE | EGFR-targeting-BiTE | Intratumoral | Preclinical | [121] | PBMC or T cells | ||
Solid tumor | VCN-01 | Ad5-E2F-∆24-RGDK-PH20 | PH20 | Intravenous | Phase I | NCT02045602 | [122] | Nab-paclitaxel, gemcitabine | |
Pancreatic cancer | Intratumoral | Phase I | NCT02045589 | [123] | Gemcitabine, abraxane | ||||
Solid tumor | VCN-11 | Ad5-E2F-∆24-RGDK-PH20-ABD | PH20, albumin-binding domain (ABD) | Intravenous | Preclinical | [124] | |||
Liver cancer | hTERT | OBP-301 | Ad5-hTERT-E1A-IRES-E1B | Intratumoral | Phase I | NCT02293850 | [116] | ||
Esophageal cancer | Phase I | NCT03213054 | [125] | Radiotherapy | |||||
Solid tumor | Phase I | NCT03172819 | Pembrolizumab | ||||||
Bone and soft tissue sarcomas | OBP-405 | Ad5-hTERT-E1A-IRES-E1B-RGD | Intratumoral | Preclinical | [118] | ||||
Pancreatic cancer | OBP-502 | Ad5-hTERT-E1A-IRES-E1B-RGD-p53 | p53 | Intratumoral | Preclinical | [126] | Anti-PD-1 monotherapy | ||
Pancreatic cancer | OBP-702 | Ad5-hTERT-E1A-IRES-E1B-RGD-p53 | p53 | Intratumoral | Preclinical | [127] | Anti-PD-L1 monotherapy | ||
Solid tumor | Ad3-hTERT-E1A | Preclinical | [128] | Chemotherapy | |||||
Prostate cancer | Ad3-hTERT-CMV-CD40L | CD40L | Preclinical | [114] | |||||
Solid tumor | KGHV500 | Ad5-hTERT-E1A-IRES-E1B-RGD | anti-p21Ras scFv | Preclinical | [129] | ||||
Liver cancer | AFP | SynOV1.1 | Ad5-AFP-∆24-RGD-GM-CSF | GM-CSF | Intratumoral | Phase I | NCT04612504 | ||
Ad5-AFP-NOS- 3/RSV | Nitric Oxide Synthase Type III (NOS-3) | Intravenous | Preclinical | [130] |